The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarstons Regulatory News (MARS)

Share Price Information for Marstons (MARS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.25
Bid: 27.10
Ask: 27.20
Change: 0.00 (0.00%)
Spread: 0.10 (0.369%)
Open: 27.00
High: 27.25
Low: 27.00
Prev. Close: 27.25
MARS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 Mar 2024 16:24

RNS Number : 6993F
Marston's PLC
05 March 2024
 

5 March 2024

 

Notification of interests of directors and persons discharging managerial responsibilities

 

Marston's PLC (the "Company") announces that on 4 March 2024 the Directors listed below were granted awards over ordinary shares in the Company under the Company's Long Term Incentive Plan (the "Plan").

 

The number of shares over which awards were granted was calculated using the market price at the close of trading on the London Stock Exchange on 4 March 2024, being £0.2925 per ordinary share, save for the award granted to Hayleigh Lupino, where a notional share price of 33p was used to reflect the Remuneration Committee's decision to grant her an award over shares worth 125% of her base salary when the share price was 33p (which has decreased since that decision).

 

Awards under the Plan comprise two elements:

 

(i) a nil-cost option (a "Nil-Cost Option"), and

 

(ii) a CSOP Option over shares with a total value at the date of grant of £60,000 (the statutory limit) with an exercise price of £0.2925 per share (a "CSOP Option").

 

Performance Metrics

 

Nil-Cost Options will vest to the extent performance conditions are satisfied as set out below:

 

Measure

Weighting

Threshold (25% vest)

Maximum (100% vest)

Underlying PBT in 20261

20%

£75m

£95m

Net cash flow2 (2024, 2025 and 2026 aggregate)

40%

£150m

£180m

Operating Margin in 2026

20%

16.3%

18.3%

Relative Total Shareholder Return (TSR) (measured over FY2023/24 to FY2025/2026)

20%

Median

Upper quartile

1. Underlying PBT: exclusive of income from associates.

2. Net cash inflow/(outflow) as per the Net Debt note to the financial statements.

3. Straight-line vesting applies between Threshold and Maximum.

 

To the extent the performance metrics are met, a Nil-Cost Option will be released following the end of a further two-year holding period.

 

Linking Arrangement between Nil-Cost Option and CSOP Option

 

The options have been granted such that the maximum pre-tax value delivered to the participant will not exceed the value of the shares over which the Nil-Cost Option would have vested if it was a standalone option.

 

The CSOP option will be released only to the extent that the aggregate CSOP gain is less than or equal to the value of the shares over which the Nil-Cost Option would be released on the normal release date.

 

Name

Designation

Number of shares subject to CSOP Option

Number of shares subject to Nil-Cost Option

Justin Platt

 

Director

205,128

 

2,871,795

 

Hayleigh Lupino

Director

205,128

 

1,347,041

 

 

Enquiries:

Bethan Raybould, General Counsel & Company Secretary, Marston's PLC, +44 (0) 1902 907250

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Justin Platt

 

2.

Reason for the notification

a)

Position/status

Director and PDMR (Chief Executive Officer)

 

b)

Initial notification/ amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Marston's PLC

b)

LEI code

213800Q6RP3ZJ2CZR962

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 7.375 pence each

 

 

ISIN: GB00B1JQDM80

b)

Nature of the transaction

Grant of awards under the Marston's PLC Long Term Incentive Plan in the form of a CSOP option with an exercise price of £0.2925 per share and a nil-cost option.

 

c)

Price(s) and volumes(s)

 

Price

Volume

Nil-cost option: N/A

2,871,795

CSOP option: £0.2925

 

205,128

d)

Aggregated information

- Aggregate volume

 

- Price

 

 

N/A

 

e)

Date of the transaction

2024-03-04

f)

Place of the transaction

Outside a trading venue

 

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Hayleigh Lupino

 

2.

Reason for the notification

a)

Position/status

Director and PDMR (Chief Financial Officer)

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Marston's PLC

b)

LEI code

213800Q6RP3ZJ2CZR962

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 7.375 pence each

 

 

ISIN: GB00B1JQDM80

b)

Nature of the transaction

Grant of awards under the Marston's PLC Long Term Incentive Plan in the form of a CSOP option with an exercise price of £0.2925 per share and a nil-cost option.

c)

Price(s) and volumes(s)

 

Price

Volume

Nil-cost option: N/A

205,128

CSOP option: £0.2925

1,347,041

d)

Aggregated information

- Aggregate volume

 

- Price

 

 

N/A

 

e)

Date of the transaction

2024-03-04

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAKDSEAALEFA
Date   Source Headline
28th Mar 20242:50 pmRNSDirector/PDMR Shareholding
15th Mar 202410:15 amRNSDirector/PDMR Shareholding
11th Mar 20247:00 amRNSSuccession plan to appoint new Chair of the Board
7th Mar 202410:03 amRNSDirector Declaration
6th Mar 20248:35 amRNSDirector/PDMR Shareholding
5th Mar 20244:24 pmRNSDirector/PDMR Shareholding
1st Mar 202412:58 pmRNSTotal Voting Rights
9th Feb 20248:40 amRNSHolding(s) in Company
7th Feb 20244:08 pmRNSHolding(s) in Company
2nd Feb 202411:14 amRNSDirector/PDMR Shareholding
1st Feb 20244:26 pmRNSHolding(s) in Company
31st Jan 20241:52 pmRNSHolding(s) in Company
23rd Jan 20241:30 pmRNSResult of AGM
23rd Jan 20247:00 amRNSTrading for the 16-week period to 20 January 2024
9th Jan 20241:57 pmRNSBlock listing Interim Review
20th Dec 20234:16 pmRNSAnnual Financial Report
5th Dec 20237:00 amRNSPRELIMINARY RESULTS
1st Dec 20232:30 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSDirectorate Change
22nd Nov 20232:02 pmRNSHolding(s) in Company
17th Nov 20237:00 amRNSMarston’s PLC appoints Justin Platt as new CEO
11th Oct 20237:00 amRNSTrading update for the 52 weeks to 30 Sep 2023
15th Aug 20233:36 pmRNSHolding(s) in Company
1st Aug 20239:30 amRNSHolding(s) in Company
26th Jul 20234:29 pmRNSHolding(s) in Company
26th Jul 20237:00 amRNSTrading update for the 42 weeks to 22 July 2023
10th Jul 20233:21 pmRNSBlock listing Interim Review
4th Jul 20232:18 pmRNSNotification of Trading Update Date
29th Jun 202310:26 amRNSDirector/PDMR Shareholding
28th Jun 20235:03 pmRNSDirector/PDMR Shareholding
28th Jun 20234:54 pmRNSDirector/PDMR Shareholding
27th Jun 20234:11 pmRNSDirector/PDMR Shareholding
26th Jun 20232:23 pmRNSDirector/PDMR Shareholding
26th Jun 20231:08 pmRNSDirector/PDMR Shareholding
25th May 20238:16 amRNSDirector/PDMR Shareholding
24th May 20238:48 amRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSRESULTS FOR THE 26 WEEKS ENDED 1 APRIL 2023
31st Mar 20237:00 amRNSAmendment and extension of debt facilities
22nd Mar 202310:19 amRNSHolding(s) in Company
24th Jan 20232:01 pmRNSResult of AGM
24th Jan 20237:00 amRNSTrading for the 16-week period to 21 January 2023
10th Jan 20233:07 pmRNSBlock listing Interim Review
6th Jan 20233:11 pmRNSHolding(s) in Company
3rd Jan 20239:42 amRNSHolding(s) in Company
21st Dec 20225:05 pmRNSConfirmation of Covenant Amendments
21st Dec 20222:34 pmRNSAnnual Financial Report
14th Dec 20229:00 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSPreliminary Results for 52 weeks ended 1 Oct 2022
5th Dec 202212:31 pmRNSConfirmation of Final Results announcement date
30th Nov 202210:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.